索拉费尼布作为转移性阴道黑色素瘤的第一线治疗:一个多中心,安慰剂控制的随机停药研究 (STREAM)
Halime Kalkavan1,2,3,4, Max E Scheulen1,2, Eckhart Kämpgen5,6
1Medical Faculty, University Duisburg-Essen, 45147 Essen, Germany.
iScience
|December 9, 2025
概括
多酶抑制剂索拉费尼布显著改善了以前未接受过治疗的转移性阴道黑色素瘤 (mUM) 患者的无进展生存率. 这种一线治疗耐受性很好,为mUM患者提供了一个有前途的选择.
科学领域:
- 在瘤学瘤学.
- 医学遗传学 医学遗传学
背景情况:
- 转移性阴道黑色素瘤 (mUM) 预后不佳,全身治疗选择有限.
- 疾病的快速进展和短暂生存是mUM的特征.
研究的目的:
- 评估索拉费尼布作为转移性乳膜黑色素瘤患者的一线治疗的疗效和安全性.
- 评估GNAQ/GNA11突变对治疗结果的影响.
主要方法:
- 一个多中心,安慰剂控制,随机性停药第二阶段试验.
- 147名从未接受过治疗的MUM患者在56天的试验期内接受了索拉费尼布.
- 78名病情稳定的患者被随机分为1:1接受盲目的索拉费尼布或安慰剂.
主要成果:
- 与安慰剂相比,索拉芬尼显著增加了无进展生存时间 (PFS) 的中位数 (5.5 vs 1.9 个月;HR=0.53;p=0.0083).
- 第一线索拉费尼布显示出有前途的疗效,在mUM患者队列中耐受性良好.
- 在基线循环瘤DNA (ctDNA) 中的GNAQ/GNA11突变与较差的结果相关.
结论:
- 索拉费尼布是一种有效且耐受性良好的第一线全身治疗转移性乳膜黑色素瘤的系统疗法.
- 该研究满足了其主要终点,证明了索拉芬尼对PFS的显著益处.
- 在mUM中,GNAQ/GNA11突变状态可以作为预后生物标志物.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.4K
05:46Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
2.1K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...